Open Access

Hsp60 and human aging: Les liaisons dangereuses

Francesco Cappello1,2,*,Everly Conway De Macario3,Antonella Marino Gammazza1,2,Giuseppe Bonaventura1,Francesco Carini1,Anna M. Czarnecka4,Felicia Farina1,Giovanni Zummo1,Alberto J. L. Macario2,3
Department of Experimental Biomedicine and Clinical Neurosciences, Human Anatomy Section Emerico Luna, University of Palermo, Palermo, Italy
IEMEST, Istituto Euro-Mediterraneo di Scienza e Tecnologia, Palermo, Italy
Department of Microbiology and Immunology, School of Medicine, University of Maryland at Baltimore, and IMET, Baltimore (MD), USA
Department of Laboratory of Molecular Oncology, Department of Oncology, Military Institute of Medicine, ul. Szaserów 128, 01-141 Warsaw, Poland
DOI: 10.2741/4126 Volume 18 Issue 2, pp.626-637
Published: 01 January 2013
(This article belongs to the Special Issue Frontiers in cancer research and treatment)
*Corresponding Author(s):  
Francesco Cappello

Stressors can cause abnormal intracellular accumulation of Hsp60 and its localization in extramitochondrial sites, secretion, and circulation, with immune system activation. Dysfunction of chaperones associated with their quantitative and qualitative decline with aging (chaperonopathies of aging) characterizes senescence and is a potential causal factor in the physiological deterioration that occurs with it. The role of Hsp60 in aging is not easy to elucidate, because aging is accompanied by pathologies (e.g., cardiovascular and neurodegenerative disorders, osteoporosis, diabetes, cancer, etc.) in which Hsp60 has been implicated but, although those disorders are more frequent in the elderly, they are not unique to them. Therefore, it is difficult to determine what is due to aging and what to an associated disease that can occur regardless of age. Does Hsp60 contribute to the pathogenesis? How and when does Hsp60 interact with the immune system and, thus, contributes to the initiation- progression of the generalized chronic inflammation characteristic of aging? These and related issues are discussed here in the light of reports showing the participation of Hsp60 in aging-associated disorders.

Key words

Hsp60, Chaperoning system, Chaperonin, Hsp10, Senescence, Chaperonopathies, Chaperonotherapy, Review

Share and Cite
Francesco Cappello, Everly Conway De Macario, Antonella Marino Gammazza, Giuseppe Bonaventura, Francesco Carini, Anna M. Czarnecka, Felicia Farina, Giovanni Zummo, Alberto J. L. Macario. Hsp60 and human aging: Les liaisons dangereuses. Frontiers in Bioscience-Landmark. 2013. 18(2); 626-637.